Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. ucrxf

UCRxF

A novel ulcerative colitis treatment - A phase III ready feasibility study

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 UCRxF project word cloud

Explore the words cloud of the UCRxF project. It provides you a very rough idea of what is the project "UCRxF" about.

payments    reinvested    unmet    international    pharmaceuticals    uc    milestone    2018    prior    sales    immunomodulatory    license    ab    primary    biological    commercial    ready    immunological    platform    preparation    upfront    generate    mechanism    business    moderate    efficacy    demonstrated    company    index    sequences    diseases    debilitating    action    caused    innovative    colon    inflammation    severe    cobitolimod    clinical    drugs    reported    fast    acute    q4    continue    broad    manufacturing    line    portfolio    partnering    cure    revenues    companies    dna    medication    institutet    medical    dims    active    sweden    deal    profile    compounds    patients    preparations    karolinska    safety    party    additional    attractiveness    toxicology    science    disease    feasibility    initiation    ulcerative    colitis    iib    licensing    tested    asset    treat    pharmaceutical    chronic    treatment    approved    park    offers    purpose    stockholm    planning    larger    royalties    efficient    drug    strategy    finance   

Project "UCRxF" data sheet

The following table provides information about the project.

Coordinator		 INDEX PHARMACEUTICALS AB 

Organization address
address: TOMTEBODAVAGEN 23A
city: STOCKHOLM
postcode: 171 77
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Sweden [SE]
 Project website https://www.indexpharma.com/en/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-05-01   to  2018-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INDEX PHARMACEUTICALS AB SE (STOCKHOLM) coordinator 50˙000.00

Map

 Project objective

InDex Pharmaceuticals AB is a pharmaceutical development company based at the Karolinska Institutet Science Park in Stockholm, Sweden. The company´s primary asset is cobitolimod, which is in late phase clinical development as a new medication to treat moderate to severe active ulcerative colitis (UC); a chronic, debilitating disease with a high unmet medical need. UC is caused by chronic inflammation of the colon, and there is no cure.

Cobitolimod offers a novel and unique mechanism of action for the treatment of UC, and has demonstrated a higher efficacy and better safety profile in clinical studies than what has been reported for currently approved biological drugs. Cobitolimod is part of the broad InDex portfolio of DNA-based ImmunoModulatory Sequences (referred to as DIMS), which have the potential for treatment of various immunological diseases. Cobitolimod is currently being tested in a phase IIb clinical study with top line results expected in Q4 2018.

InDex’s business strategy is to out-license cobitolimod to a larger international pharmaceutical company prior to the initiation of clinical phase III development. This will generate revenues for InDex from upfront and milestone payments as well as royalties from third party sales, which can then be reinvested in the company to finance development of new compounds from the DIMS technology platform.

For clinical phase III, additional manufacturing and toxicology work as well as commercial preparations are essential. The planning and preparation of this work is the purpose of this feasibility study, which is a crucial part of the cobitolimod phase III ready programme, increasing the attractiveness of the asset in partnering discussions with pharmaceutical companies looking for innovative new products. A licensing deal will ensure that the development of this promising, innovative drug will continue in a fast and efficient way to reach patients with this debilitating disease.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "UCRXF" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "UCRXF" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

BeatsDigTherapeutics (2019)

Project SCALE: Tailored Digital Therapeutics for Neurological and Brain Disorders

Read More